Abstract
Selling innovative drugs and generic drugs is as different as selling rockets and sneakers. It is, therefore, not surprising that innovative pharma companies have difficulties in developing strategies for entering and exploiting selected generic markets. In spite of barriers to entry, their interest in specific generic segments is definitely high. And we do believe that this interest will result in increasing generic activity of innovative pharma players — even if selling sneakers requires building new capabilities for rocket traders.
Keywords
Get full access to this article
View all access options for this article.